GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (LTS:0A87) » Definitions » Book Value per Share

Takeda Pharmaceutical Co (LTS:0A87) Book Value per Share : $15.27 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Takeda Pharmaceutical Co Book Value per Share?

Takeda Pharmaceutical Co's book value per share for the quarter that ended in Sep. 2024 was $15.27.

During the past 12 months, Takeda Pharmaceutical Co's average Book Value Per Share Growth Rate was -3.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 11.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 7.80% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Takeda Pharmaceutical Co was 14.40% per year. The lowest was -8.10% per year. And the median was 4.50% per year.

Takeda Pharmaceutical Co's current price is $13.5318. Its book value per share for the quarter that ended in Sep. 2024 was $15.27. Hence, today's PB Ratio of Takeda Pharmaceutical Co is 0.89.

During the past 13 years, the highest P/B Ratio of Takeda Pharmaceutical Co was 2.46. The lowest was 0.82. And the median was 1.29.


Takeda Pharmaceutical Co Book Value per Share Historical Data

The historical data trend for Takeda Pharmaceutical Co's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Book Value per Share Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.08 15.22 15.37 15.29 15.47

Takeda Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.24 14.92 15.47 15.74 15.27

Competitive Comparison of Takeda Pharmaceutical Co's Book Value per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's PB Ratio falls into.



Takeda Pharmaceutical Co Book Value per Share Calculation

Takeda Pharmaceutical Co's Book Value Per Share for the fiscal year that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(48,547-0)/3,138
=15.47

Takeda Pharmaceutical Co's Book Value Per Share for the quarter that ended in Sep. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(48,412-0)/3,170
=15.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Takeda Pharmaceutical Co  (LTS:0A87) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Takeda Pharmaceutical Co Book Value per Share Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co Headlines

No Headlines